Aprea Q1 net loss $3.3M ($0.22/sh); cash $46.5M; APR-1051 shows two partial responses

Aprea Therapeutics, Inc.

Cash and equivalents $46.5M as of Mar 31, 2026, up from $14.6M year-end 2025; runway into Q1 2028.
Operating loss $3.4M for Q1 2026 vs $4.1M in Q1 2025; R&D expense fell to $1.6M from $2.5M.
WEE1 inhibitor APR-1051: two partial responses observed; dose escalation ongoing; ASCO 2026 presentation on May 30.
Oversubscribed $30M private placement closed Mar 31, 2026, led by Soleus Capital to expand APR-1051 enrollment.
ATRN-119 (ATR inhibitor) monotherapy paused; evaluating combination approaches including with radiation.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Aprea Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 13, 2026, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026, and provided an update on the Company’s operations for the same period.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-059734

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.